Figure 2
Figure 2. Effects of Ly49G2+ or Ly49C/I+ NK-cell subset depletion on β2m−/− BMC rejection by B6, B10, and B10.D2 recipients. Recipient mice received mAbs for NK-cell subset depletion using anti-Ly49C/I (5E6), anti-Ly49G2 (4D11) mAbs or rIgG control 2 and one day before lethal irradiation. (A-B) A total of 15 million or (C) 50 million of β2m−/− BMCs were transferred intravenously in (A) B6 (H2b), (B) B10 (H2b), and (C) B10.D2 (H2d) recipients, respectively. Anti-NK1.1 (PK136) was used 2 and one day before BMT to remove all NK1.1-positive cells in some groups to demonstrate that BMC rejection was the result of host NK cells. In all experiments, 7 days after transplantation, hematopoietic progenitor content of the spleens (total CFU-c per spleen) was assessed (mean ± SEM). One-way ANOVA test was performed to determine whether the mean values were significantly different (P < .05). Each experiment was performed 2 or 3 times.

Effects of Ly49G2+ or Ly49C/I+ NK-cell subset depletion on β2m−/− BMC rejection by B6, B10, and B10.D2 recipients. Recipient mice received mAbs for NK-cell subset depletion using anti-Ly49C/I (5E6), anti-Ly49G2 (4D11) mAbs or rIgG control 2 and one day before lethal irradiation. (A-B) A total of 15 million or (C) 50 million of β2m−/− BMCs were transferred intravenously in (A) B6 (H2b), (B) B10 (H2b), and (C) B10.D2 (H2d) recipients, respectively. Anti-NK1.1 (PK136) was used 2 and one day before BMT to remove all NK1.1-positive cells in some groups to demonstrate that BMC rejection was the result of host NK cells. In all experiments, 7 days after transplantation, hematopoietic progenitor content of the spleens (total CFU-c per spleen) was assessed (mean ± SEM). One-way ANOVA test was performed to determine whether the mean values were significantly different (P < .05). Each experiment was performed 2 or 3 times.

Close Modal

or Create an Account

Close Modal
Close Modal